I. E. Smith

2.3k total citations · 1 hit paper
37 papers, 1.7k citations indexed

About

I. E. Smith is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, I. E. Smith has authored 37 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in I. E. Smith's work include Estrogen and related hormone effects (9 papers), Breast Cancer Treatment Studies (9 papers) and Lung Cancer Research Studies (7 papers). I. E. Smith is often cited by papers focused on Estrogen and related hormone effects (9 papers), Breast Cancer Treatment Studies (9 papers) and Lung Cancer Research Studies (7 papers). I. E. Smith collaborates with scholars based in United Kingdom, United States and Australia. I. E. Smith's co-authors include Mitch Dowsett, Alwynne Tidy, T.J. Powles, S. Ashley, S.J. Harland, A. Hilary Calvert, Janine Salter, T J McElwain, David R. Newell and H.T. Ford and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

I. E. Smith

37 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II

1982 408 citations A. Hilary Calvert, S.J. Harland et al. Cancer Chemotherapy and Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
I. E. Smith United Kingdom	16	900	597	485	422	340	37	1.7k
Enrico Ricevuto Italy	24	942 1.0×	284 0.5×	623 1.3×	379 0.9×	465 1.4×	121	2.0k
Hiroshi Sonoo Japan	26	1.3k 1.5×	476 0.8×	820 1.7×	645 1.5×	292 0.9×	123	2.3k
Yuichi Takatsuka Japan	22	940 1.0×	371 0.6×	306 0.6×	707 1.7×	261 0.8×	91	1.7k
Richard A. Bender United States	22	857 1.0×	205 0.3×	587 1.2×	514 1.2×	260 0.8×	69	1.9k
Giorgio Cocconi Italy	25	1.4k 1.6×	223 0.4×	431 0.9×	421 1.0×	769 2.3×	85	2.2k
J R Farndon United Kingdom	17	1.5k 1.7×	492 0.8×	701 1.4×	610 1.4×	324 1.0×	39	2.3k
Edda Simoncini Italy	26	1.7k 1.9×	360 0.6×	440 0.9×	1.1k 2.5×	753 2.2×	99	2.5k
Carol L. Rosenberg United States	26	1.1k 1.2×	552 0.9×	944 1.9×	750 1.8×	212 0.6×	39	2.3k
Marc E. Lippman United States	13	1.0k 1.1×	474 0.8×	792 1.6×	854 2.0×	207 0.6×	16	2.2k
A. U. Buzdar United States	18	1.2k 1.4×	422 0.7×	379 0.8×	930 2.2×	299 0.9×	46	2.1k

Countries citing papers authored by I. E. Smith

Since Specialization

Citations

This map shows the geographic impact of I. E. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. E. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. E. Smith more than expected).

Fields of papers citing papers by I. E. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. E. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. E. Smith. The network helps show where I. E. Smith may publish in the future.

Co-authorship network of co-authors of I. E. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of I. E. Smith. A scholar is included among the top collaborators of I. E. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. E. Smith. I. E. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Okines, Alicia, Emma Kipps, Maria Coakley, et al.. (2019). Impact of delayed adjuvant chemotherapy: The Royal Marsden Hospital (RMH) experience. Annals of Oncology. 30. iii28–iii28. 1 indexed citations

Arnedos, Mónica, Maria Afentakis, Roger A’Hern, et al.. (2014). Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Annals of Oncology. 25(3). 605–610. 30 indexed citations

Huober, J., Jian Wu, Anita Giobbie‐Hurder, et al.. (2011). Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial.. Journal of Clinical Oncology. 29(15_suppl). 522–522. 6 indexed citations

Smith, I. E., L. Johnson, Mitch Dowsett, et al.. (2011). Trial of perioperative endocrine therapy: Individualizing care (POETIC).. Journal of Clinical Oncology. 29(15_suppl). TPS117–TPS117. 2 indexed citations

Cristofanilli, Massimo, Rachel Schiff, V. Valero, et al.. (2009). Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). 1014–1014. 10 indexed citations

Powles, T.J., S. Ashley, Alwynne Tidy, I. E. Smith, & Mitch Dowsett. (2007). Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial. JNCI Journal of the National Cancer Institute. 99(4). 283–290. 309 indexed citations

Yau, Thomas, et al.. (2004). Time and chemotherapy treatments trends in the elderly (age>70) with lung cancer in a single UK cancer centre. Journal of Clinical Oncology. 22(14_suppl). 7128–7128. 2 indexed citations

Saccani‐Jotti, Gloria, I. E. Smith, Janine Salter, et al.. (1995). Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.. PubMed. 55(15). 3331–8. 254 indexed citations

Kedar, R P, David O. Cosgrove, I. E. Smith, Janine Mansi, & Jeffrey C. Bamber. (1994). Breast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging.. Radiology. 190(3). 825–830. 76 indexed citations

10.

Jones, A, I. E. Smith, Helena Earl, et al.. (1993). Urinary-derived Monocyte-Colony Stimulating Factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC). Annals of Oncology. 4(10). 877–881. 1 indexed citations

11.

Adshead, Fiona, et al.. (1991). Small Cell Carcinoma of the Prostate: Implications for Management. British Journal of Urology. 67(2). 217–219. 13 indexed citations

12.

Hoskin, Peter, et al.. (1991). Intercalated radio-chemotherapy in small cell lung cancer: toxicity and implications for future regimens. Radiotherapy and Oncology. 20(3). 177–180. 2 indexed citations

13.

Glaholm, J., Lazzaro Repetto, John Yarnold, et al.. (1988). Carboplatin (JM8), etoposide (VP16) and thoracic Irradiation for small cell lung cancer (S.C.L.C.): An evaluation of lung toxicity. Radiotherapy and Oncology. 12(1). 31–37. 8 indexed citations

14.

Harland, S.J., et al.. (1986). Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemotherapy and Pharmacology. 18(3). 284–5. 50 indexed citations

15.

Belle, S.J.P. Van, et al.. (1986). Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. Cancer Chemotherapy and Pharmacology. 18(1). 27–32. 38 indexed citations

16.

Stuart‐Harris, R., David W. Hedley, Ian W. Taylor, Arnold Levene, & I. E. Smith. (1985). Tumour ploidy, response and survival in patients receiving endocrine therapy for advanced breast cancer. British Journal of Cancer. 51(4). 573–576. 33 indexed citations

17.

Evans, B D, I. E. Smith, R D Clutterbuck, & Jeremy Millar. (1983). Normal tissue toxicity and antitumour experiments carried out in mice using high-dose cyclophosphamide. Cancer Treatment Reviews. 10. 25–32. 5 indexed citations

18.

Muindi, Josephia R., David R. Newell, I. E. Smith, & K.R. Harrap. (1983). Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies. British Journal of Cancer. 47(1). 27–33. 9 indexed citations

19.

Anderson, Jane, Jasmine Hunt, & I. E. Smith. (1981). Prevention of doxorubicin-induced alopecia by scalp cooling in patients with advanced breast cancer.. BMJ. 282(6262). 423–424. 39 indexed citations

20.

Ford, H.T., et al.. (1980). PREVENTION OF ISOPHOSPHAMIDE-INDUCED UROTHELIAL TOXICITY WITH 2-MERCAPTOETHANE SULPHONATE SODIUM (MESNUM) IN PATIENTS WITH ADVANCED CARCINOMA. The Lancet. 316(8196). 657–659. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact